생물제제 충전 및 완제 시장 : 업계 동향과 세계 예측(-2035년) - 1차 포장 용기 유형별, 제조 생물제제 유형별, 사업 규모별, 치료 영역별, 최종사용자별, 기업 유형별, 기업 규모별, 지역별

Biologics Fill Finish Manufacturing Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Primary Packaging Container, Biologic Manufactured, Operation, Therapeutic Area, End User, Geographical Regions and Leading Players

US $ 4,799 ￦ 7,147,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,999 ￦ 10,423,000

PDF (One-Location Site License)

PDF 보고서를 동일 사업장의 특정 사업 부문에 속한 모든 분들이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,599 ￦ 15,785,000

PDF (Department License)

PDF 보고서를 부서 단위로 12명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 17,999 ￦ 26,805,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

생물제제 충전 및 완제 시장 : 개요

Roots Analysis에 따르면, 세계 생물제제 충전 및 완제 시장 규모는 2035년까지 예측 기간 동안 CAGR 6.72% 성장하여 현재 44억 달러에서 2035년까지 84억 달러에 달할 것으로 예측됩니다.

시장 규모 및 기회 분석은 다음 매개 변수를 기반으로 세분화됩니다.

1차 포장 용기 유형

• 바이알
• 주사기
• 앰플
• 카트리지

제조 생물제제 유형

• 항체
• 재조합 단백질
• 백신
• 세포치료
• 유전자 치료
• 핵산 및 올리고뉴클레오티드
• 기타

사업 규모

• 상업적 규모
• 전임상 및 임상

치료 영역

• 종양 질환
• 심혈관 질환
• 대사성 질환
• 감염성 질환
• 자가면역 질환
• 기타 질환

최종 사용자

• 제약 및 생물제제 기업
• 위탁생산기관 및 기타

기업 유형

• 산업
• 비산업

기업 규모

• 대기업
• 중견기업
• 중소기업

지역

• 북미
• 유럽
• 아시아태평양
• 중동 및 북아프리카
• 라틴아메리카

생물제제 충전 및 완제 시장 : 성장과 동향

생물제제는 탄수화물, 단백질, 핵산 또는 이들 물질의 조합 등 다양한 생체 분자로 구성된 복잡한 치료용 분자입니다. 이러한 의약품은 일반적으로 살아있는 세포에서 얻어지며 빛, 온도, pH, 산소 농도 등 다양한 환경 요인에 매우 민감합니다. 따라서 이러한 분자의 제조는 매우 복잡하며, 발효, 무균 충전 및 포장, 온도 관리 및 적절한 보관 등 고도의 제조 공정이 필요합니다.

특히, 생물제제의 최종 충전 및 포장 공정은 생물제제의 다운스트림 처리에서 매우 중요한 단계입니다. 최종 포장 용기(앰플, 카트리지, 프리필드시린지, 바이알 등)에 충전할 때 제품의 무균 상태를 유지하기 위해 특정 취급 절차를 엄격하게 준수해야 합니다. 또한, 제조 공정에서 보고된 모든 불일치는 미생물 오염으로 이어질 수 있습니다. 그 결과, 제품 손실, 개발 일정의 연장, 그리고 의약품 개발 기업에게 큰 재정적 부담이 발생합니다.

이러한 생물제제의 충전 및 마무리와 관련된 복잡성과 과제 때문에 더 많은 제약회사들이 충전 및 마무리 공정의 아웃소싱 업체로 위탁생산기관(CMO)이나 위탁개발생산기관(CDMO)에 집중하는 경향이 있습니다. 특기할 만한 점은 제약 개발 기업의 25% 이상이 충진 및 마무리 공정의 외주화를 선택하고 있다는 점입니다. 이 분야의 아웃소싱 증가 추세는 생물제제 충전 및 완제 기업이 오염 위험 감소와 정확한 충전 보장, 제품 손실률 감소에 필수적인 클린룸을 갖춘 첨단 시설과 필요한 기술을 보유하고 있기 때문입니다.

또한, CMO는 자동화, 로봇공학, 인공지능의 통합과 같은 첨단 기술을 활용하여 충전 공정의 효율성, 수율 향상, 품질 기준 준수를 지원합니다. 이를 통해 시장 출시 속도를 가속화하고 제품의 잠재적 리스크를 최소화할 수 있습니다. 따라서 생물제제에 대한 수요 증가와 충진 및 마무리 공정의 효율화를 위한 기술 발전은 예측 기간 동안 생물제제 충진 및 마감제조 분야의 주요 촉진요인으로 작용하여 시장 성장에 크게 기여할 것으로 예측됩니다.

생물제제 충전 및 완제 시장 : 주요 인사이트

이 보고서는 생물제제의 충전 및 마감제조 시장의 현황을 상세하게 분석하고 업계의 잠재적인 성장 기회를 파악합니다. 보고서의 주요 내용은 다음과 같습니다.

• 현재 약 255개의 서비스 제공업체가 다양한 생물제제에 대한 충전 및 마무리 서비스를 제공하고 있으며, 그 중 30% 이상이 미국에 본사를 두고 있습니다.
• 서비스 제공업체의 55% 이상이 고객의 다양한 충진 및 마감 요구 사항을 충족시키기 위해 모든 규모의 사업을 운영하고 있습니다. 특히, 바이알이 가장 널리 채택된 1차 포장 용기로 부상하고 있습니다.
• 경쟁 우위를 확보하고 진화하는 업계 표준에 대응하기 위해 이해관계자들은 각 회사의 생물제제 충전 및 포장 서비스 포트폴리오를 강화하고 기존 역량을 강화하기 위해 적극적으로 노력하고 있습니다.
• 이 분야에서 체결된 거래의 30% 이상이 인수합병이며, 그 중 대부분은 이해관계자들이 지역적 사업기반을 강화하기 위해 체결한 대륙 내 거래였습니다.
• 생물제제에 대한 수요 증가에 힘입어 CMO(위탁생산기관)들은 기존 생산 능력과 기능 확충에 많은 투자를 하고 있습니다. 50% 이상의 확장률을 보이는 미국에서는 이러한 추세가 가장 두드러지게 나타나고 있습니다.

• 전 세계 생물제제 충전 및 마무리 설비 용량은 다양한 지역에 널리 분포되어 있습니다. 흥미롭게도 전체 설비 용량의 약 80%가 대규모 및 초대형 기업 소유의 시설에 집중되어 있습니다.
• 생물제제 파이프라인의 확장에 따라 충전 및 마무리 서비스 수요가 급증하고 있으며, 2035년까지 향후 10년간 CAGR 12.11% 수요 증가가 예상됩니다.
• 만성질환 치료용 생물제제에 대한 수요가 빠르게 증가하고 있는 점을 감안할 때, 생물제제 충전 및 완제품 제조 시장은 2035년까지 연평균 6.72%의 성장률을 보일 것으로 예측됩니다.
• 대규모 위탁생산기관(CMO)이 생물제제 충전 및 완제의약품 분야 매출의 대부분을 차지할 것으로 예측됩니다. 또한, 자가면역질환 치료에 사용되는 생물제제의 충전 및 마무리 시장은 2035년까지 더 빠른 속도로 성장할 것으로 예측됩니다.

• 다수의 CMO의 존재와 첨단 충전 및 마감 기술에 대한 쉬운 접근성 등 여러 가지 구체적인 요인에 힘입어 미국의 생물제제 충전 및 마감 시장은 연평균 5.18%의 성장률을 보일 것으로 예측됩니다.

생물제제 충진 및 마감제조 시장 : 주요 분야

제공되는 서비스 유형에 따라 시장은 API(원료의약품)와 FDF(완제의약품)로 구분됩니다. 현재 생물제제 충전 및 완제품 제조 시장의 대부분을 API가 차지하고 있다는 점은 주목할 만합니다. 이는 생물제제의 API 제조에는 시설비(개발 및 유지), 재료비, 인건비, 기타 많은 부대비용을 포함한 막대한 자본 투자가 필요하기 때문입니다. 따라서 이해관계자들은 API 생산에 있어 위탁생산업체(CMO)의 전문 지식에 의존하고 있습니다.

제조 생물제제 유형별로 시장은 항체, 세포치료제, 백신, 기타 생물제제, 기타 생물제제로 세분화됩니다. 특히 주목할 점은 항체가 생물제제 위탁생산 시장에서 가장 큰 비중을 차지하고 있다는 점입니다. 이는 전 세계적으로 100가지 이상의 항체가 승인되었고, 항체 관련 임상시험의 수가 증가하는 추세에 기인합니다.

사용되는 발현 시스템 유형에 따라 시장은 포유류 시스템, 미생물 시스템, 기타로 세분화됩니다. 현재 포유류계 발현 시스템을 채택한 생물제제 프로젝트를 통한 수익이 시장을 주도하고 있다는 점은 주목할 만합니다. 이는 높은 단백질 수율, 우수한 접힘 특성 및 번역 후 변형, 배치 간 균일성 향상 등의 장점으로 인해 이 시스템의 활용이 확대되고 있기 때문인 것으로 보입니다.

운영 규모에 따라 시장은 전임상/임상 규모와 상업적 규모로 구분됩니다. 상업적 규모의 제조가 전체 시장을 주도할 것으로 예상되는 반면, 전임상/임상 규모의 생물제제 제조 시장은 상대적으로 높은 CAGR로 성장할 가능성이 높다는 점에 유의해야 합니다.

기업 규모에 따라 시장은 중소기업, 중견기업, 대기업 및 초대형 기업으로 구분됩니다. 대기업 및 초대형 기업이 상대적으로 높은 시장 점유율을 차지하고 있는 반면, 중소기업의 생물제제 충진 및 마감제조 시장은 향후 몇 년 동안 큰 폭의 성장이 예상된다는 점에 주목해야 합니다.

<

주요 지역별로 북미, 유럽, 아시아태평양, 중동 및 북아프리카, 라틴아메리카로 구분됩니다. 특히 아시아태평양 시장은 향후 몇 년 동안 더 높은 CAGR로 성장할 것으로 예측됩니다.

생물제제 충진 및 마감제조 시장의 대표 기업

• AbbVie Contract Manufacturing
• Alcami
• Asymchem
• Boehringer Ingelheim BioXcellence
• Bushu Pharmaceuticals
• Catalent Biologics
• Cenexi
• Charles River
• CordenPharma
• Curia
• Elements Material Technology
• Evonik
• Fareva
• Fresenius Kabi
• Grand River Aseptic Manufacturing
• GSK
• Hetero
• Lifecore Biomedical
• Lonza
• Northway Biotechpharma
• Novocol Pharma
• Patheon pharma services
• Pharmaceutics International(Pii)
• Rechon Life Science
• Recipharm
• Syngene
• WACKER
• WuXi Biologics

목차

섹션 I : 보고서 개요

제1장 서문

제2장 조사 방법

제3장 시장 역학

제4장 거시경제 지표

섹션 II : 정성적 인사이트

제5장 주요 요약

제6장 서론

• 본 장의 개요
• 생물제제 입문
• 생물제제 관련 업무의 아웃소싱 필요성
• 생물제제 업계에서 수탁 제조업체의 역할
• 생물제제 업계에서 일반적으로 아웃소싱 되는 업무
• 충전/마무리 서비스 제공업체를 선택할 때에 고려해야 할 중요 점
• 충전 및 완제 업무 아웃소싱의 이점
• 충전 및 완제 업무 아웃소싱에 수반하는 리스크와 과제
• 결론

섹션 III : 시장 개요

제7장 시장 구도

• 본 장의 개요
• 생물제제 충전 및 완제 서비스 제공업체 : 시장 구도

제8장 기업 경쟁력 분석

• 본 장의 개요
• 전제와 주요 파라미터
• 조사 방법
• 피어 그룹 개요
• 생물제제 충전 및 완제 서비스 제공업체 : 기업 경쟁력 분석

섹션 IV : 기업 개요

제9장 기업 개요 : 북미의 생물제제 충전 및 완제 서비스 제공업체

• 본 장의 개요
• AbbVie Contract Manufacturing
• Alcami
• Catalent Biologics
• Charles River
• Curia
• Grand River Aseptic Manufacturing
• Lifecore Biomedical
• Novocol Pharma
• Patheon pharma services
• Pharmaceutics International(Pii)

제10장 기업 개요 : 유럽의 생물제제 충전 및 완제 서비스 제공업체

• 본 장의 개요
• Boehringer Ingelheim BioXcellence
• Cenexi
• CordenPharma
• Element Materials Technology
• Evonik
• Fareva
• Fresenius Kabi
• GSK
• Lonza
• Northway Biotechpharma
• Rechon Life Science
• Recipharm
• WACKER

제11장 기업 개요 : 아시아태평양의 생물제제 충전 및 완제 서비스 제공업체

• 본 장의 개요
• Asymchem
• Bushu Pharmaceuticals
• Hetero
• Syngene
• WuXi Biologics

섹션 V : 시장 동향

제12장 파트너십 및 협업

• 본 장의 개요
• 파트너십 모델
• 생물제제 충전 및 완제 서비스 제공업체 : 파트너십 및 협업

제13장 최근 확장

제14장 생물제제 충전 및 완제 업무 전략적 아웃소싱 : 능력 갭 평가

제15장 용량 분석

제16장 수요 분석

제17장 지역 능력 분석

섹션 VI : 시장 기회 분석

제18장 시장 영향 분석

• 본 장의 개요
• 시장 성장 촉진요인
• 시장 성장 억제요인
• 시장 기회
• 시장이 해결해야 할 과제
• 결론

제19장 세계의의 생물제제 충전 및 완제 시장

제20장 생물제제 충전 및 완제 시장(1차 포장 용기 유형별)

제21장 생물제제 충전 및 완제 시장(제조 생물제제 유형별)

제22장 생물제제 충전 및 완제 시장(사업 규모별)

제23장 생물제제 충전 및 완제 시장(치료 영역별)

제24장 생물제제 충전 및 완제 시장(최종사용자별)

제25장 생물제제 충전 및 완제 시장(기업 유형별)

제26장 생물제제 충전 및 완제 시장(기업 규모별)

제27장 북미의 생물제제 충전 및 완제 시장

제28장 유럽의 생물제제 충전 및 완제 시장

제29장 아시아태평양의 생물제제 충전 및 완제 시장

LSH

영문 목차

영문목차

BIOLOGICS FILL FINISH MANUFACTURING MARKET: OVERVIEW

As per Roots Analysis, the global biologics fill finish manufacturing market is estimated to grow from USD 4.4 billion in the current year to USD 8.4 billion by 2035, at a CAGR of 6.72% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Primary Packaging Container

• Vials
• Syringes
• Ampoules
• Cartridges

Type of Biologic Manufactured

• Antibodies
• Recombinant Proteins
• Vaccines
• Cell Therapies
• Gene Therapies
• Nucleic Acids / Oligonucleotides
• Other Biologics

Scale of Operation

• Commercial
• Preclinical / Clinical

Therapeutic Area

• Oncological Disorders
• Cardiovascular Disorders
• Metabolic Diseases
• Infectious Diseases
• Autoimmune Disorders
• Other Disorders

End User

• Pharmaceutical / Biopharmaceutical Companies
• Contract Manufacturing Organizations / Others

Type of Player

• Industry
• Non-industry

Company Size

• Large Companies
• Mid-sized Companies
• Small Companies

Geographical Regions

• North America
• Europe
• Asia-Pacific
• Middle East and North Africa
• Latin America

BIOLOGICS FILL FINISH MANUFACTURING MARKET: GROWTH AND TRENDS

Biologics are complex therapeutic molecules comprising of various biomolecules, such as carbohydrates, proteins, nucleic acids or a combination of these substances. These drugs are typically obtained from living cells and are very responsive to different environmental factors, such as light, temperature, pH and oxygen levels. As a result, the production of these molecules is quite complex and necessitates advanced manufacturing processes, such as fermentation, sterile fill finish, and adequate storage with controlled temperatures.

Significantly, the fill finish of biologics is an essential phase in the downstream processing of biopharmaceuticals, wherein specific handling protocols must be followed in order to maintain the product's sterility during filling in final packaging containers (such as ampoules, cartridges, prefilled syringes, and vials). Also, any inconsistencies reported in production may lead to microbial contamination. This results in product loss, extended development schedules, and significant financial strain on drug developers.

Due to such complexities and challenges related to the fill / finish of biologics, more drug developers are shifting their focus towards contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) for outsourcing their fill finish processes. It is important to mention that over 25% of pharmaceutical developers choose to outsource the fill finish processes. This increased trend of outsourcing in this sector can be attributed to the capability of biologics fill finish manufacturing firms having the required skills and advanced facilities with clean rooms, which are crucial for lowering contamination risks and ensuring accurate filling while decreasing product loss rates.

In addition, CMOs leverage cutting-edge technologies (such as automation, robotics and incorporation of artificial intelligence) that assist in enhancing the filling process, boosting yield, and adhering to quality standards, thereby accelerating the speed to reach the market and minimizing any potential risk of the product. Therefore, the growing demand for biologics along with technological advancements to improve the efficiency of fill finish process are likely to be the key drivers in the biologics fill finish manufacturing sector, contributing significantly to the market growth, during the forecast period.

BIOLOGICS FILL FINISH MANUFACTURING MARKET: KEY INSIGHTS

The report delves into the current state of the biologics fill finish manufacturing market and identifies potential growth opportunities within industry. Some key findings from the report include:

• Presently, close to 255 service providers are engaged in offering fill / finish services for various biologic drugs; of these, over 30% of the service providers are headquartered in the US.
• Over 55% of the service providers operate at all scales of operation to cater to the diverse fill / finish requirements of their clients; notably, vials have emerged as the most adopted primary packaging container.
• In pursuit of gaining a competitive edge and to meet the evolving industry standards, stakeholders are actively enhancing their existing capabilities by improving their respective biologics fill / finish service portfolios.
• More than 30% of the deals inked in this domain are acquisitions; of these, majority of the agreements were intracontinental deals signed by the stakeholders to strengthen their regional footprint.
• Driven by the growing demand for biologics, CMOs have made considerable investments to expand their existing capacities and capabilities; with over 50% expansions, this trend is most pronounced in the US.

• The global installed biologics fill / finish capacity is well distributed across various geographies; interestingly, close to 80% of the total installed capacity is available in facilities owned by large and very large players.
• Given the growing pipeline of biologic drug products, the demand for fill / finish services has upsurged; by 2035, the demand is expected to grow at a CAGR of 12.11% over the next decade.
• Given the rapid increase in the demand of biologics for the treatment of chronic conditions, the biologics fill / finish manufacturing market is poised to grow at a CAGR of 6.72% till 2035.
• Large CMOs are likely to generate majority of the revenues in the biologics fill / finish domain; further, fill / finish market for biologics used in treatment of autoimmune disorders is anticipated to grow at a faster pace till 2035.

• Driven by numerous tangible factors, such as the presence of a large number of CMOs and easy access to advanced fill / finish technologies, the biologics fill / finish market in the US is likely to grow at CAGR of 5.18%.

BIOLOGICS FILL FINISH MANUFACTURING MARKET: KEY SEGMENTS

Contract Manufacturing Market for API is Likely to Dominate the Biologics Fill Finish Manufacturing Market During the Forecast Period

Based on the type of service(s) offered, the market is segmented into API and FDF. It is worth highlighting that majority of the current biologics fill finish manufacturing market is captured by APIs. This can be attributed to the fact that manufacturing of biopharmaceuticals API demand significant capital investments, which include facility costs (development and maintenance), material costs, labor costs and a number of other ancillary expenses. Therefore, stakeholders rely on the expertise of CMOs for API production.

Cell Therapies is the Fastest Growing Segment of the Biologics Fill Finish Manufacturing Market During the Forecast Period

Based on the type of biologic manufactured, the market is segmented into antibodies, cell therapies, vaccines and other biologics. It is worth highlighting the antibodies capture the maximum share within the biopharmaceutical contract manufacturing market. This can be attributed to the fact that more than 100 antibodies have been approved across the globe and an increasing number of clinical trials related to antibodies are also underway.

Mammalian Expression System is Expected to Capture the Highest Share of the Biologics Fill Finish Manufacturing Market During the Forecast Period

Based on the type of expression system used, the market is segmented into mammalian, microbial and others. It is worth highlighting that currently, the market is likely to be driven by revenues generated through biopharmaceutical projects employing mammalian expression systems. This can be attributed to the higher usage of such systems owing to their high protein yielding ability, enhanced folding and post-translational modifications, and improved batch-to-batch uniformity.

By Scale of Operation, Commercial Scale is Likely to Dominate the Biologics Fill Finish Manufacturing Market During the Forecast Period

Based on the scale of operation, the market is segmented into preclinical / clinical and commercial scale. Whilst commercial scale manufacturing is projected to be the primary driver of the overall market, it is worth highlighting that the biologics manufacturing market at preclinical / clinical scale is likely to grow at a relatively higher CAGR.

Large and Very Large Companies Hold Maximum Share within the Biologics Manufacturing Market

Based on company size, the market is segmented into small companies, mid-sized, and large and very large companies. While large and very large companies account for a relatively higher market share, it is worth highlighting that the Biologics Fill Finish Manufacturing Market for small companies is likely to witness substantial market growth in the coming years.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America. It is worth highlighting that over the years, the market in Asia-Pacific is expected to grow at a higher CAGR.

Example Players in the Biologics Fill Finish Manufacturing Market

• AbbVie Contract Manufacturing
• Alcami
• Asymchem
• Boehringer Ingelheim BioXcellence
• Bushu Pharmaceuticals
• Catalent Biologics
• Cenexi
• Charles River
• CordenPharma
• Curia
• Elements Material Technology
• Evonik
• Fareva
• Fresenius Kabi
• Grand River Aseptic Manufacturing
• GSK
• Hetero
• Lifecore Biomedical
• Lonza
• Northway Biotechpharma
• Novocol Pharma
• Patheon pharma services
• Pharmaceutics International (Pii)
• Rechon Life Science
• Recipharm
• Syngene
• WACKER
• WuXi Biologics

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

• Senior Director Drug Product Sales, Large Company, US
• Business Development Manager, Mid-sized Company, Netherlands
• Marketing Specialist, Mid-sized Company, Poland
• Vice President and Head of Formulations, Very Large Company, India
• Former Vice President, Business Development and Marketing, Mid-sized Company, US
• Former Technology Watch Manager, Mid-sized Company, France
• Head of Business Development, Mid-sized Company, Czech Republic
• Former Chief Commercial Officer, Large Company, Germany
• Former Global Business Development Manager, Mid-sized Company, Netherlands

BIOLOGICS FILL FINISH MANUFACTURING MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: The report features a thorough analysis of the global biologics fill finish manufacturing market, in terms of the key market segments, including [A] type of primary packaging container, [B] type of biologic manufactured, [C] scale of operation, [D] therapeutic area, [E] end user, [F] type of player, [G] Company Size, and [H] geographical regions.
• Market Landscape: An in-depth assessment of the companies involved in biologics fill finish manufacturing market, based on several relevant parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] location of fill / finish facilities , [E] scale of operation [F] type of biologic manufactured, [G] presence of cytostatic or cytotoxic or highly potent substance filling capability, [H] type of dosage form [I] type of primary packaging container used and [J] additional services offered.
• Company Competitive Analysis: A comprehensive analysis of biologics fill / finish service providers based across the key geographical regions, such as [A] North America [B] Europe and [C] Asia-Pacific, and rest of the world.
• Company Profiles: Detailed profiles of key service providers across North America, Europe and Asia-Pacific engaged in the biologics fill finish manufacturing market, focused on parameters such as [A] company overview, [B] financial information (if available), [C] service portfolio, [D] manufacturing facilities and [E] recent developments and an informed future outlook.
• Partnerships and Collaborations: An in-depth analysis of the partnership's activity reported in this domain, based on parameters such as [A] year of partnership, [B] type of partnership [C] scale of operation, and [D] type of partner company.
• Recent Expansions: A detailed analysis of expansion initiatives undertaken by biologics fill finish service provider, during the period along with information on several relevant parameters, such as [A] year of expansion, [B] type of expansion, [C] area of expanded facility and [D] scale of operation.
• Strategic Outsourcing in Biopharmaceutical Fill / Finish Operations: A comprehensive framework to evaluate the capability gaps within the biologics fill finish manufacturing market highlighting information on the key trends observed across [A] small companies [B] mid-sized companies, [C] large companies and [D] very large companies.
• Capacity Analysis: An estimate of the overall installed capacity for the manufacturing of biologics, highlighting the distribution of the available capacity, based on [A] biologics fill / finish capacity for ampoules, [B] biologics fill / finish capacity for cartridges and [C] biologics fill / finish capacity for syringes, [D] biologics fill / finish capacity for vials.
• Demand Analysis: An informed estimate of the annual demand for biologics, based on various relevant parameters, such as [A] scale of operation, [B] type of primary packaging container used and [C] geography.
• Regional Capability Analysis: A detailed regional analysis of biologics fill finish manufacturers based on various parameters across [A] North America, [B] Europe, [C] Asia-Pacific and rest of the World.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

SECTION I: REPORT OVERVIEW

1. PREFACE

• 1.1. Introduction
• 1.2. Market Share Insights
• 1.3. Key Market Insights
• 1.4. Report Coverage
• 1.5. Key Questions Answered
• 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

• 2.1. Chapter Overview
• 2.2. Research Assumptions
  • 2.2.1. Market Landscape and Market Trends
  • 2.2.2. Market Forecast and Opportunity Analysis
  • 2.2.3. Comparative Analysis
• 2.3. Database Building
  • 2.3.1. Data Collection
  • 2.3.2. Data Validation
  • 2.3.3. Data Analysis
• 2.4. Project Methodology
  • 2.4.1. Secondary Research
    • 2.4.1.1. Annual Reports
    • 2.4.1.2. Academic Research Papers
    • 2.4.1.3. Company Websites
    • 2.4.1.4. Investor Presentations
    • 2.4.1.5. Regulatory Filings
    • 2.4.1.6. White Papers
    • 2.4.1.7. Industry Publications
    • 2.4.1.8. Conferences and Seminars
    • 2.4.1.9. Government Portals
    • 2.4.1.10. Media and Press Releases
    • 2.4.1.11. Newsletters
    • 2.4.1.12. Industry Databases
    • 2.4.1.13. Roots Proprietary Databases
    • 2.4.1.14. Paid Databases and Sources
    • 2.4.1.15. Social Media Portals
    • 2.4.1.16. Other Secondary Sources
  • 2.4.2. Primary Research
    • 2.4.2.1. Types of Primary Research
      • 2.4.2.1.1. Qualitative Research
      • 2.4.2.1.2. Quantitative Research
      • 2.4.2.1.3. Hybrid Approach
    • 2.4.2.2. Advantages of Primary Research
    • 2.4.2.3. Techniques for Primary Research
      • 2.4.2.3.1. Interviews
      • 2.4.2.3.2. Surveys
      • 2.4.2.3.3. Focus Groups
      • 2.4.2.3.4. Observational Research
      • 2.4.2.3.5. Social Media Interactions
    • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
      • 2.4.2.4.1. Company Executives (CXOs)
      • 2.4.2.4.2. Board of Directors
      • 2.4.2.4.3. Company Presidents and Vice Presidents
      • 2.4.2.4.4. Research and Development Heads
      • 2.4.2.4.5. Technical Experts
      • 2.4.2.4.6. Subject Matter Experts
      • 2.4.2.4.7. Scientists
      • 2.4.2.4.8. Doctors and Other Healthcare Providers
    • 2.4.2.5. Ethics and Integrity
      • 2.4.2.5.1. Research Ethics
      • 2.4.2.5.2. Data Integrity
  • 2.4.3. Analytical Tools and Databases
• 2.5. Robust Quality Control

3. MARKET DYNAMICS

• 3.1. Chapter Overview
• 3.2. Forecast Methodology
  • 3.2.1. Top-down Approach
  • 3.2.2. Bottom-up Approach
  • 3.2.3. Hybrid Approach
• 3.3. Market Assessment Framework
  • 3.3.1. Total Addressable Market (TAM)
  • 3.3.2. Serviceable Addressable Market (SAM)
  • 3.3.3. Serviceable Obtainable Market (SOM)
  • 3.3.4. Currently Acquired Market (CAM)
• 3.4. Forecasting Tools and Techniques
  • 3.4.1. Qualitative Forecasting
  • 3.4.2. Correlation
  • 3.4.3. Regression
  • 3.4.4. Extrapolation
  • 3.4.5. Convergence
  • 3.4.6. Sensitivity Analysis
  • 3.4.7. Scenario Planning
  • 3.4.8. Data Visualization
  • 3.4.9. Time Series Analysis
  • 3.4.10. Forecast Error Analysis
• 3.5. Key Considerations
  • 3.5.1. Demographics
  • 3.5.2. Government Regulations
  • 3.5.3. Reimbursement Scenarios
  • 3.5.4. Market Access
  • 3.5.5. Supply Chain
  • 3.5.6. Industry Consolidation
  • 3.5.7. Pandemic / Unforeseen Disruptions Impact
• 3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

• 4.1. Chapter Overview
• 4.2. Market Dynamics
  • 4.2.1. Time Period
    • 4.2.1.1. Historical Trends
    • 4.2.1.2. Current and Forecasted Estimates
  • 4.2.2. Currency Coverage
    • 4.2.2.1. Major Currencies Affecting the Market
    • 4.2.2.2. Factors Affecting Currency Fluctuations
    • 4.2.2.3. Impact of Currency Fluctuations on the Industry
  • 4.2.3. Foreign Currency Exchange Rate
    • 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
    • 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
  • 4.2.4. Recession
    • 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
  • 4.2.5. Inflation
    • 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
    • 4.2.5.2. Potential Impact of Inflation on the Market Evolution
  • 4.2.6. Interest Rates
    • 4.2.6.1. Interest Rates and Their Impact on the Market
    • 4.2.6.2. Strategies for Managing Interest Rate Risk
  • 4.2.7. Commodity Flow Analysis
    • 4.2.7.1. Type of Commodity
    • 4.2.7.2. Origins and Destinations
    • 4.2.7.3. Value and Weights
    • 4.2.7.4. Modes of Transportation
  • 4.2.8. Global Trade Dynamics
    • 4.2.8.1. Import Scenario
    • 4.2.8.2. Export Scenario
    • 4.2.8.3. Trade Policies
    • 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
    • 4.2.8.5. Impact of Trade Barriers on the Market
  • 4.2.9. War Impact Analysis
    • 4.2.9.1. Russian-Ukraine War
    • 4.2.9.2. Israel-Hamas War
  • 4.2.10. COVID Impact / Related Factors
    • 4.2.10.1. Global Economic Impact
    • 4.2.10.2. Industry-specific Impact
    • 4.2.10.3. Government Response and Stimulus Measures
    • 4.2.10.4. Future Outlook and Adaptation Strategies
  • 4.2.11. Other Indicators
    • 4.2.11.1. Fiscal Policy
    • 4.2.11.2. Consumer Spending
    • 4.2.11.3. Gross Domestic Product (GDP)
    • 4.2.11.4. Employment
    • 4.2.11.5. Taxes
    • 4.2.11.6. Stock Market Performance
    • 4.2.11.7. Cross-Border Dynamics
• 4.3. Conclusion

SECTION II: QUALITATIVE INSIGHTS

5. EXECUTIVE SUMMARY

6. INTRODUCTION

• 6.1. Chapter Overview
• 6.2. Introduction to Biologics
• 6.3. Need for Outsourcing Biologics-related Operations
• 6.4. Role of Contract Manufacturers in the Biopharmaceutical Industry
• 6.5. Commonly Outsourced Operations in the Biopharmaceutical Industry
  • 6.5.1. Biologics Fill / Finish Operations
• 6.6. Key Considerations while Selecting a Fill / Finish Service Provider
• 6.7. Advantages of Outsourcing Fill / Finish Operations
• 6.8. Risks and Challenges associated with Outsourcing Fill / Finish Operations
• 6.9. Conclusion

SECTION III: MARKET OVERVIEW

7. MARKET LANDSCAPE

• 7.1. Chapter Overview
• 7.2. Biologics Fill / Finish Service Providers: Overall Market Landscape
  • 7.2.1. Analysis by Year of Establishment
  • 7.2.2. Analysis by Company Size
  • 7.2.3. Analysis by Location of Headquarters
  • 7.2.4. Analysis by Location of Fill / Finish Facilities
  • 7.2.5. Analysis by Scale of Operation
  • 7.2.6. Analysis by Type of Biologic Manufactured
  • 7.2.7. Analysis by Presence of Cytostatic or Cytotoxic or Highly Potent Substance Filling Capability
  • 7.2.8. Analysis by Type of Dosage Form
  • 7.2.9. Analysis by Type of Primary Packaging Container Used
  • 7.2.10. Analysis by Additional Services Offered

8. COMPANY COMPETITIVENESS ANALYSIS

• 8.1. Chapter Overview
• 8.2. Assumptions and Key Parameters
• 8.3. Methodology
• 8.4. Overview of Peer Groups
• 8.5. Biologics Fill / Finish Service Providers: Company Competitiveness Analysis
  • 8.5.1. Biologics Fill / Finish Service Providers based in North America (Peer Group I)
  • 8.5.2. Biologics Fill / Finish Service Providers based in Europe (Peer Group II)
  • 8.5.3. Biologics Fill / Finish Service Providers based in Asia-Pacific and Rest of the World (Peer Group III)

SECTION IV: COMPANY PROFILES

9. COMPANY PROFILES: BIOLOGICS FILL / FINISH SERVICE PROVIDERS IN NORTH AMERICA

• 9.1. Chapter Overview
• 9.2. AbbVie Contract Manufacturing
  • 9.2.1. Company Overview
  • 9.2.2. Financial Information
  • 9.2.3. Biologics Fill / Finish Service Portfolio
  • 9.2.4. Recent Developments and Future Outlook
• 9.3. Alcami
• 9.4. Catalent Biologics
• 9.5. Charles River
• 9.6. Curia
• 9.7. Grand River Aseptic Manufacturing
• 9.8. Lifecore Biomedical
• 9.9. Novocol Pharma
• 9.10. Patheon pharma services
• 9.11. Pharmaceutics International (Pii)

10. COMPANY PROFILES: BIOLOGICS FILL / FINISH SERVICE PROVIDERS IN EUROPE

• 10.1. Chapter Overview
• 10.2. Boehringer Ingelheim BioXcellence
  • 10.2.1. Company Overview
  • 10.2.2. Financial Information
  • 10.2.3. Biologics Fill / Finish Service Portfolio
  • 10.2.4. Recent Developments and Future Outlook
• 10.3. Cenexi
• 10.4. CordenPharma
• 10.5. Element Materials Technology
• 10.6. Evonik
• 10.7. Fareva
• 10.8. Fresenius Kabi
• 10.9. GSK
• 10.10. Lonza
• 10.11. Northway Biotechpharma
• 10.12. Rechon Life Science
• 10.13. Recipharm
• 10.14. WACKER

11. COMPANY PROFILES: BIOLOGICS FILL / FINISH SERVICE PROVIDERS IN ASIA-PACIFIC

• 11.1. Chapter Overview
• 11.2. Asymchem
  • 11.2.1. Company Overview
  • 11.2.2. Financial Information
  • 11.2.3. Biologics Fill / Finish Service Portfolio
  • 11.2.4. Recent Developments and Future Outlook
• 11.3. Bushu Pharmaceuticals
• 11.4. Hetero
• 11.5. Syngene
• 11.6. WuXi Biologics

SECTION V: MARKET TRENDS

12. PARTNERSHIPS AND COLLABORATIONS

• 12.1. Chapter Overview
• 12.2. Partnership Models
• 12.3. Biologics Fill / Finish Service Providers: Partnerships and Collaborations
  • 12.3.1. Analysis by Year of Partnership
  • 12.3.2. Analysis by Type of Partnership
  • 12.3.3. Analysis by Year and Type of Partnership
  • 12.3.4. Analysis by Scale of Operation
  • 12.3.5. Analysis by Type of Partner Company
  • 12.3.6. Most Active Players: Analysis by Number of Partnerships
  • 12.3.7. Analysis by Geography
    • 12.3.7.1. Local and International Agreements
    • 12.3.7.2. Intracontinental and Intercontinental Agreements

13. RECENT EXPANSIONS

• 13.1. Chapter Overview
• 13.2. Expansion Models
• 13.3. Biologics Fill / Finish Service Providers: Recent Expansions
  • 13.3.1. Analysis by Year of Expansion
  • 13.3.2. Analysis by Type of Expansion
  • 13.3.3. Analysis by Year and Type of Expansion
  • 13.3.4. Analysis by Location of Expanded Facility
  • 13.3.5. Analysis by Type of Expansion and Location of Expanded Facility
  • 13.3.6. Analysis by Area of Expanded Facility
  • 13.3.7. Analysis by Scale of Operation
  • 13.3.8. Analysis by Type of Primary Packaging Container Used
  • 13.3.9. Analysis by Type of Expansion and Type of Primary Packaging Container Used
  • 13.3.10. Analysis by Amount Invested
  • 13.3.11. Most Active Players: Analysis by Number of Expansion Initiatives

14. STRATEGIC OUTSOURCING IN BIOPHARMACEUTICAL FILL / FINISH OPERATIONS: EVALUATING THE CAPABILITY GAPS

• 14.1. Chapter Overview
• 14.2. Scope and Methodology
• 14.3. Key Insights
  • 14.3.1. Trends Observed across Small Companies
  • 14.3.2. Trends Observed across Mid-sized Companies
  • 14.3.3. Trends Observed across Large Companies
  • 14.3.4. Trends Observed across Very Large Companies
• 14.4. Conclusion

15. CAPACITY ANALYSIS

• 15.1. Chapter Overview
• 15.2. Global Installed Biologics Fill / Finish Capacity for Ampoules (Number of Units / Batch)
  • 15.2.1. Key Assumptions and Methodologies
  • 15.2.2. Analysis by Company Size
  • 15.2.3. Analysis by Geography
    • 15.2.3.1. Analysis of Biologics Fill / Finish Capacity for Ampoules in North America
    • 15.2.3.2. Analysis of Biologics Fill / Finish Capacity for Ampoules in Europe
    • 15.2.3.3. Analysis of Biologics Fill / Finish Capacity for Ampoules in Asia-Pacific
    • 15.2.3.4. Analysis of Biologics Fill / Finish Capacity for Ampoules in Rest of the World
• 15.3. Global Installed Biologics Fill / Finish Capacity for Cartridges (Number of Units / Batch)
  • 15.3.1. Key Assumptions and Methodologies
  • 15.3.2. Analysis by Company Size
  • 15.3.3. Analysis by Geography
    • 15.3.3.1. Analysis of Biologics Fill / Finish Capacity for Cartridges in North America
    • 15.3.3.2. Analysis of Biologics Fill / Finish Capacity for Cartridges in Europe
    • 15.3.3.3. Analysis of Biologics Fill / Finish Capacity for Cartridges in Asia-Pacific
    • 15.3.3.4. Analysis of Biologics Fill / Finish Capacity for Cartridges in Rest of the World
• 15.4. Global Installed Biologics Fill / Finish Capacity for Syringes (Number of Units / Batch)
  • 15.4.1. Key Assumptions and Methodologies
  • 15.4.2. Analysis by Company Size
  • 15.4.3. Analysis by Geography
    • 15.4.3.1. Analysis of Biologics Fill / Finish Capacity for Syringes in North America
    • 15.4.3.2. Analysis of Biologics Fill / Finish Capacity for Syringes in Europe
    • 15.4.3.3. Analysis of Biologics Fill / Finish Capacity for Syringes in Asia-Pacific
    • 15.4.3.4. Analysis of Biologics Fill / Finish Capacity for Syringes in Rest of the World
• 15.5. Global Installed Biologics Fill / Finish Capacity for Vials (Number of Units / Batch)
  • 15.5.1. Key Assumptions and Methodologies
  • 15.5.2. Analysis by Company Size
  • 15.5.3. Analysis by Geography
    • 15.5.3.1. Analysis of Biologics Fill / Finish Capacity for Vials in North America
    • 15.5.3.2. Analysis of Biologics Fill / Finish Capacity for Vials in Europe
    • 15.5.3.3. Analysis of Biologics Fill / Finish Capacity for Vials in Asia-Pacific
    • 15.5.3.4. Analysis of Biologics Fill / Finish Capacity for Vials in Rest of the World
• 15.6. Concluding Remarks

16. DEMAND ANALYSIS

• 16.1. Chapter Overview
• 16.2. Assumptions and Methodology
• 16.3. Global Annual Demand for Biologics Fill / Finish Manufacturing (in Million Liters)
  • 16.3.1. Analysis by Scale of Operation
  • 16.3.2. Analysis by Type of Primary Packaging Container Used
  • 16.3.3. Analysis by Geography

17. REGIONAL CAPABILITY ANALYSIS

• 17.1. Chapter Overview
• 17.2. Key Assumptions and Parameters
• 17.3. Biologics Fill / Finish Manufacturing Capabilities in North America
• 17.4. Biologics Fill / Finish Manufacturing Capabilities in Europe
• 17.5. Biologics Fill / Finish Manufacturing Capabilities in Asia-Pacific and Rest of the World

SECTION VI: MARKET OPPORTUNITY ANALYSIS

18. MARKET IMPACT ANALYSIS

• 18.1. Chapter Overview
• 18.2. Market Drivers
• 18.3. Market Restraints
• 18.4. Market Opportunities
• 18.5. Market Challenges
• 18.6. Conclusion

19. GLOBAL BIOLOGICS FILL / FINISH MANUFACTURING MARKET

• 19.1. Chapter Overview
• 19.2. Key Assumptions and Methodology
• 19.3. Global Biologics Fill / Finish Manufacturing Market, Forecasted Estimates, Till 2035
  • 19.3.1. Roots Analysis Perspective on Market Growth
  • 19.3.2. Multivariate Scenario Analysis
    • 19.3.2.1. Conservative Scenario
    • 19.3.2.2. Optimistic Scenario
• 19.4. Key Market Segmentations

20. BIOLOGICS FILL / FINISH MANUFACTURING MARKET, BY TYPE OF PRIMARY PACKAGING CONTAINER USED

• 20.1. Chapter Overview
• 20.2. Key Assumptions and Methodology
• 20.3. Biologics Fill / Finish Manufacturing Market: Distribution by Type of Primary Packaging Container Used
  • 20.3.1. Biologics Fill / Finish Manufacturing Market for Vials, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 20.3.2. Biologics Fill / Finish Manufacturing Market for Syringes, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 20.3.3. Biologics Fill / Finish Manufacturing Market for Ampoules, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 20.3.4. Biologics Fill / Finish Manufacturing Market for Cartridges, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
• 20.4. Biologics Fill / Finish Manufacturing Market, by Type of Primary Packaging Container Used: Market Dynamics Assessment
  • 20.4.1. Market Movement Analysis
  • 20.4.2. Penetration-Growth (P-G) Matrix
• 20.5. Data Triangulation and Validation

21. BIOLOGICS FILL / FINISH MANUFACTURING MARKET, BY TYPE OF BIOLOGIC MANUFACTURED

• 21.1. Chapter Overview
• 21.2. Key Assumptions and Methodology
• 21.3. Biologics Fill / Finish Manufacturing Market: Distribution by Type of Biologic Manufactured
  • 21.3.1. Biologics Fill / Finish Manufacturing Market for Antibodies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 21.3.2. Biologics Fill / Finish Manufacturing Market for Recombinant Proteins, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 21.3.3. Biologics Fill / Finish Manufacturing Market for Vaccines, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 21.3.4. Biologics Fill / Finish Manufacturing Market for Cell Therapies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 21.3.5. Biologics Fill / Finish Manufacturing Market for Gene Therapies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 21.3.6. Biologics Fill / Finish Manufacturing Market for Nucleic Acids / Oligonucleotides, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 21.3.7. Biologics Fill / Finish Manufacturing Market for Other Biologics, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
• 21.4. Data Triangulation and Validation

22. BIOLOGICS FILL / FINISH MANUFACTURING MARKET, BY SCALE OF OPERATION

• 22.1. Chapter Overview
• 22.2. Key Assumptions and Methodology
• 22.3. Biologics Fill / Finish Manufacturing Market: Distribution by Scale of Operation
  • 22.3.1. Biologics Fill / Finish Manufacturing Market for Commercial Scale, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 22.3.2. Biologics Fill / Finish Manufacturing Market for Preclinical / Clinical Scale, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
• 22.4. Data Triangulation and Validation

23. BIOLOGICS FILL / FINISH MANUFACTURING MARKET, BY THERAPEUTIC AREA

• 23.1. Chapter Overview
• 23.2. Key Assumptions and Methodology
• 23.3. Biologics Fill / Finish Manufacturing Market: Distribution by Therapeutic Area
  • 23.3.1. Biologics Fill / Finish Manufacturing Market for Oncological Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 23.3.2. Biologics Fill / Finish Manufacturing Market for Cardiovascular Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 23.3.3. Biologics Fill / Finish Manufacturing Market for Metabolic Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 23.3.4. Biologics Fill / Finish Manufacturing Market for Infectious Diseases, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 23.3.5. Biologics Fill / Finish Manufacturing Market for Autoimmune Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 23.3.6. Biologics Fill / Finish Manufacturing Market for Other Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
• 23.4. Data Triangulation and Validation

24. BIOLOGICS FILL / FINISH MANUFACTURING MARKET, BY END USER

• 24.1. Chapter Overview
• 24.2. Key Assumptions and Methodology
• 24.3. Biologics Fill / Finish Manufacturing Market: Distribution by End User
  • 24.3.1. Biologics Fill / Finish Manufacturing Market for Pharmaceutical / Biopharmaceutical Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 24.3.2. Biologics Fill / Finish Manufacturing Market for Contract Manufacturing Organizations and Others, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
• 24.4. Data Triangulation and Validation

25. BIOLOGICS FILL / FINISH MANUFACTURING MARKET, BY TYPE OF PLAYER

• 25.1. Chapter Overview
• 25.2. Key Assumptions and Methodology
• 25.3. Biologics Fill / Finish Manufacturing Market: Distribution by Type of Player
  • 25.3.1. Biologics Fill / Finish Manufacturing Market for Industry Players, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 25.3.2. Biologics Fill / Finish Manufacturing Market for Non-Industry Players, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
• 25.4. Data Triangulation and Validation

26. BIOLOGICS FILL / FINISH MANUFACTURING MARKET, BY COMPANY SIZE

• 26.1. Chapter Overview
• 26.2. Key Assumptions and Methodology
• 26.3. Biologics Fill / Finish Manufacturing Market: Distribution by Company Size
  • 26.3.1. Biologics Fill / Finish Manufacturing Market for Large Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 26.3.2. Biologics Fill / Finish Manufacturing Market for Mid-sized Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 26.3.3. Biologics Fill / Finish Manufacturing Market for Small Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
• 26.4. Data Triangulation and Validation

27. BIOLOGICS FILL / FINISH MANUFACTURING MARKET IN NORTH AMERICA**

• 27.1. Chapter Overview
• 27.2. Key Assumptions and Methodology
• 27.3. Biologics Fill / Finish Manufacturing Market in North America, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 27.3.1. Biologics Fill / Finish Manufacturing Market in North America: Distribution by Country
    • 27.3.1.1. Biologics Fill / Finish Manufacturing Market in the US, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 27.3.1.2. Biologics Fill / Finish Manufacturing Market in Canada, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 27.3.1.3. Biologics Fill / Finish Manufacturing Market in Mexico, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 27.3.2. Biologics Fill / Finish Manufacturing Market in North America: Distribution by Type of Primary Packaging Container Used
    • 27.3.2.1. Biologics Fill / Finish Manufacturing Market in North America for Vials, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 27.3.2.2. Biologics Fill / Finish Manufacturing Market in North America for Syringes, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 27.3.2.3. Biologics Fill / Finish Manufacturing Market in North America for Ampoules, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 27.3.2.4. Biologics Fill / Finish Manufacturing Market in North America for Cartridges, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 27.3.3. Biologics Fill / Finish Manufacturing Market in North America: Distribution by Type of Biologic Manufactured
    • 27.3.3.1. Biologics Fill / Finish Manufacturing Market in North America for Antibodies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 27.3.3.2. Biologics Fill / Finish Manufacturing Market in North America for Recombinant Proteins, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 27.3.3.3. Biologics Fill / Finish Manufacturing Market in North America for Vaccines, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 27.3.3.4. Biologics Fill / Finish Manufacturing Market in North America for Cell Therapies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 27.3.3.5. Biologics Fill / Finish Manufacturing Market in North America for Gene Therapies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 27.3.3.6. Biologics Fill / Finish Manufacturing Market in North America for Nucleic Acids / Oligonucleotides, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 27.3.3.7. Biologics Fill / Finish Manufacturing Market in North America for Other Biologics, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 27.3.4. Biologics Fill / Finish Manufacturing Market in North America: Distribution by Scale of Operation
    • 27.3.4.1. Biologics Fill / Finish Manufacturing Market in North America for Commercial Scale, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 27.3.4.2. Biologics Fill / Finish Manufacturing Market in North America for Preclinical / Clinical Scale, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 27.3.5. Biologics Fill / Finish Manufacturing Market in North America: Distribution by Therapeutic Area
    • 27.3.5.1. Biologics Fill / Finish Manufacturing Market in North America for Oncological Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 27.3.5.2. Biologics Fill / Finish Manufacturing Market in North America for Cardiovascular Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 27.3.5.3. Biologics Fill / Finish Manufacturing Market in North America for Metabolic Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 27.3.5.4. Biologics Fill / Finish Manufacturing Market in North America for Infectious Diseases, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 27.3.5.5. Biologics Fill / Finish Manufacturing Market in North America for Autoimmune Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 27.3.5.6. Biologics Fill / Finish Manufacturing Market in North America for Other Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 27.3.6. Biologics Fill / Finish Manufacturing Market in North America: Distribution by End User
    • 27.3.6.1. Biologics Fill / Finish Manufacturing Market in North America for Pharmaceutical / Biopharmaceutical Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 27.3.6.2. Biologics Fill / Finish Manufacturing Market in North America for Contract Manufacturing Organizations and Others, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 27.3.7. Biologics Fill / Finish Manufacturing Market in North America: Distribution by Type of Player
    • 27.3.7.1. Biologics Fill / Finish Manufacturing Market in North America for Industry Players, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 27.3.7.2. Biologics Fill / Finish Manufacturing Market in North America for Non- Industry Players, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 27.3.8. Biologics Fill / Finish Manufacturing Market in North America: Distribution by Company Size
    • 27.3.8.1. Biologics Fill / Finish Manufacturing Market in North America for Large Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 27.3.8.2. Biologics Fill / Finish Manufacturing Market in North America for Mid-sized Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 27.3.8.3. Biologics Fill / Finish Manufacturing Market in North America for Small Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
• 27.4. Data Triangulation and Validation

28. BIOLOGICS FILL / FINISH MANUFACTURING MARKET IN EUROPE**

• 28.1. Chapter Overview
• 28.2. Key Assumptions and Methodology
• 28.3. Biologics Fill / Finish Manufacturing Market in Europe, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 28.3.1. Biologics Fill / Finish Manufacturing Market in Europe: Distribution by Country
    • 28.3.1.1. Biologics Fill / Finish Manufacturing Market in Germany, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 28.3.1.2. Biologics Fill / Finish Manufacturing Market in France, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 28.3.1.3. Biologics Fill / Finish Manufacturing Market in the UK, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 28.3.1.4. Biologics Fill / Finish Manufacturing Market in Switzerland, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 28.3.1.5. Biologics Fill / Finish Manufacturing Market in Belgium, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 28.3.1.6. Biologics Fill / Finish Manufacturing Market in Italy, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 28.3.1.7. Biologics Fill / Finish Manufacturing Market in Austria, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 28.3.1.8. Biologics Fill / Finish Manufacturing Market in Spain, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 28.3.1.9. Biologics Fill / Finish Manufacturing Market in Netherlands, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 28.3.1.10. Biologics Fill / Finish Manufacturing Market in Poland, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 28.3.1.11. Biologics Fill / Finish Manufacturing Market in Portugal, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 28.3.1.12. Biologics Fill / Finish Manufacturing Market in Rest of Europe, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 28.3.2. Biologics Fill / Finish Manufacturing Market in Europe: Distribution by Type of Primary Packaging Container Used
    • 28.3.2.1. Biologics Fill / Finish Manufacturing Market in Europe for Vials, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 28.3.2.2. Biologics Fill / Finish Manufacturing Market in Europe for Syringes, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 28.3.2.3. Biologics Fill / Finish Manufacturing Market in Europe for Ampoules, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 28.3.2.4. Biologics Fill / Finish Manufacturing Market in Europe for Cartridges, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 28.3.3. Biologics Fill / Finish Manufacturing Market in Europe: Distribution by Type of Biologic Manufactured
    • 28.3.3.1. Biologics Fill / Finish Manufacturing Market in Europe for Antibodies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 28.3.3.2. Biologics Fill / Finish Manufacturing Market in Europe for Recombinant Proteins, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 28.3.3.3. Biologics Fill / Finish Manufacturing Market in Europe for Vaccines, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 28.3.3.4. Biologics Fill / Finish Manufacturing Market in Europe for Cell Therapies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 28.3.3.5. Biologics Fill / Finish Manufacturing Market in Europe for Gene Therapies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 28.3.3.6. Biologics Fill / Finish Manufacturing Market in Europe for Nucleic Acids / Oligonucleotides, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 28.3.3.7. Biologics Fill / Finish Manufacturing Market in Europe for Other Biologics, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 28.3.4. Biologics Fill / Finish Manufacturing Market in Europe: Distribution by Scale of Operation
    • 28.3.4.1. Biologics Fill / Finish Manufacturing Market in Europe for Commercial Scale, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 28.3.4.2. Biologics Fill / Finish Manufacturing Market in Europe for Preclinical / Clinical Scale, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 28.3.5. Biologics Fill / Finish Manufacturing Market in Europe: Distribution by Therapeutic Area
    • 28.3.5.1. Biologics Fill / Finish Manufacturing Market in Europe for Oncological Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 28.3.5.2. Biologics Fill / Finish Manufacturing Market in Europe for Cardiovascular Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 28.3.5.3. Biologics Fill / Finish Manufacturing Market in Europe for Metabolic Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 28.3.5.4. Biologics Fill / Finish Manufacturing Market in Europe for Infectious Diseases, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 28.3.5.5. Biologics Fill / Finish Manufacturing Market in Europe for Autoimmune Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 28.3.5.6. Biologics Fill / Finish Manufacturing Market in Europe for Other Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 28.3.6. Biologics Fill / Finish Manufacturing Market in Europe: Distribution by End User
    • 28.3.6.1. Biologics Fill / Finish Manufacturing Market in Europe for Pharmaceutical / Biopharmaceutical Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 28.3.6.2. Biologics Fill / Finish Manufacturing Market in Europe for Contract Manufacturing Organizations and Others, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 28.3.7. Biologics Fill / Finish Manufacturing Market in Europe: Distribution by Type of Player
    • 28.3.7.1. Biologics Fill / Finish Manufacturing Market in Europe for Industry Players, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 28.3.7.2. Biologics Fill / Finish Manufacturing Market in Europe for Non- Industry Players, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 28.3.8. Biologics Fill / Finish Manufacturing Market in Europe: Distribution by Company Size
    • 28.3.8.1. Biologics Fill / Finish Manufacturing Market in Europe for Large Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 28.3.8.2. Biologics Fill / Finish Manufacturing Market in Europe for Mid-sized Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 28.3.8.3. Biologics Fill / Finish Manufacturing Market in Europe for Small Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
• 28.4. Data Triangulation and Validation

29. BIOLOGICS FILL / FINISH MANUFACTURING MARKET IN ASIA-PACIFIC**

• 29.1. Chapter Overview
• 29.2. Key Assumptions and Methodology
• 29.3. Biologics Fill / Finish Manufacturing Market in Asia-Pacific, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 29.3.1. Biologics Fill / Finish Manufacturing Market in Asia-Pacific: Distribution by Country
    • 29.3.1.1. Biologics Fill / Finish Manufacturing Market in China, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 29.3.1.2. Biologics Fill / Finish Manufacturing Market in India, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 29.3.1.3. Biologics Fill / Finish Manufacturing Market in South Korea, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 29.3.1.4. Biologics Fill / Finish Manufacturing Market in Taiwan, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 29.3.1.5. Biologics Fill / Finish Manufacturing Market in Japan, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 29.3.1.6. Biologics Fill / Finish Manufacturing Market in Singapore, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 29.3.1.7. Biologics Fill / Finish Manufacturing Market in Australia, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 29.3.1.8. Biologics Fill / Finish Manufacturing Market in Rest of Asia-Pacific, Historical Trends (since 2018) and Forecasted Estimates

관련자료